Trials
Study area | Active Centers | Enrolled Patients | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | ||
Abacus | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 11 | 12 |
Adiuvo | 43 | 0 | 0 | 0 | 0 | 1 | 3 | 6 | 19 | 31 | 43 | 51 | 63 | 73 | 79 | 91 | 91 |
ASCT-RT | 21 | 22 | 53 | 84 | 119 | 162 | 221 | 256 | 298 | 341 | 381 | 429 | 430 | 430 | 431 | 431 | 431 |
Audit Ovaio | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 265 | 555 | 630 |
BonEnza | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 16 | 18 |
CCANDY | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 60 | 137 | 192 | 218 | 218 | 218 |
COROP | 1 | 0 | 0 | 0 | 0 | 10 | 466 | 466 | 466 | 466 | 466 | 466 | 466 | 466 | 466 | 466 | 466 |
DRTST | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 37 | 40 |
EARLY | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 11 | 13 |
EndoRing | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 295 | 951 | 951 | 951 |
ENOAPA | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 36 | 71 | 102 | 137 | 170 | 210 | 213 |
EPoS | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 7 | 50 | 52 |
EUDRACT 2004-003495-11 | 21 | 0 | 3 | 18 | 32 | 48 | 62 | 63 | 65 | 65 | 65 | 65 | 65 | 65 | 65 | 65 | 65 |
FIL DLCL10 | 27 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11 | 24 | 43 | 65 | 88 | 112 | 112 | 112 |
FIL FLAZ12 | 49 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 | 32 | 66 | 89 | 113 | 135 | 154 | 154 |
FIL PanAL10 | 17 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 21 | 33 | 35 | 35 | 35 | 35 | 35 | 35 |
FIL R2-B | 34 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 16 | 42 | 42 | 42 | 42 | 42 | 42 | 42 |
FIL RBAC500 | 43 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 18 | 51 | 57 | 57 | 57 | 57 | 57 | 57 |
FUCSAM | 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 | 386 | 928 | 1556 | 1836 | 1836 | 1836 |
FUSE | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 287 | 687 | 687 | 687 | 687 | 687 |
GIMURELL LLC | 13 | 0 | 4 | 17 | 29 | 34 | 35 | 35 | 35 | 35 | 35 | 35 | 35 | 35 | 35 | 35 | 35 |
GIMURELL REAL07 | 23 | 0 | 0 | 0 | 0 | 9 | 18 | 39 | 66 | 66 | 66 | 66 | 66 | 66 | 66 | 66 | 66 |
GIMURELL ZETAL07 | 12 | 0 | 0 | 0 | 1 | 5 | 21 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 |
IIL BRIL06 | 22 | 0 | 0 | 3 | 36 | 53 | 53 | 53 | 53 | 53 | 53 | 53 | 53 | 53 | 53 | 53 | 53 |
IIL DLCL04 | 77 | 0 | 0 | 47 | 126 | 239 | 333 | 399 | 399 | 399 | 399 | 399 | 399 | 399 | 399 | 399 | 399 |
IIL FLE09 | 35 | 0 | 0 | 0 | 0 | 0 | 3 | 27 | 80 | 80 | 80 | 80 | 80 | 80 | 80 | 80 | 80 |
IIL HD0801 | 30 | 0 | 0 | 0 | 0 | 12 | 98 | 222 | 344 | 475 | 520 | 520 | 520 | 520 | 520 | 520 | 520 |
IIL HD0802 | 38 | 0 | 0 | 0 | 0 | 0 | 24 | 88 | 146 | 194 | 228 | 255 | 265 | 265 | 265 | 265 | 265 |
IIL HD0803 | 35 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 26 | 49 | 50 | 50 | 50 | 50 | 50 | 50 | 50 |
IIL LEN-DEX MCL07 | 14 | 0 | 0 | 0 | 0 | 10 | 33 | 33 | 33 | 33 | 33 | 33 | 33 | 33 | 33 | 33 | 33 |
IIL MCL0208 | 52 | 0 | 0 | 0 | 0 | 0 | 0 | 19 | 70 | 133 | 201 | 265 | 300 | 300 | 300 | 300 | 300 |
Itavision | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 793 | 935 |
LCI ADR | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 350 | 484 |
MDS ATO-AISSM02A | 13 | 0 | 5 | 21 | 33 | 44 | 44 | 44 | 44 | 44 | 44 | 44 | 44 | 44 | 44 | 44 | 44 |
MDS DECI2009-AISSM06 | 19 | 0 | 0 | 0 | 0 | 0 | 0 | 19 | 43 | 43 | 43 | 43 | 43 | 43 | 43 | 43 | 43 |
MDS EPO2006-AISSM04 | 9 | 0 | 0 | 0 | 2 | 32 | 55 | 71 | 71 | 71 | 71 | 71 | 71 | 71 | 71 | 71 | 71 |
MDS Registro | 104 | 909 | 1036 | 1184 | 1290 | 1434 | 1613 | 1931 | 2418 | 3020 | 3569 | 4049 | 4425 | 4694 | 4956 | 5123 | 5162 |
MWA vs SABR | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 4 | 4 | 4 |
NAC-GC-01 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
Osteo-REC | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 5 | 8 | 8 | 8 | 8 | 8 | 8 |
Osteo-REC 2015 | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 5 | 7 | 7 |
PON-PC-02 | 28 | 1 | 1 | 1 | 1 | 1 | 1 | 12 | 69 | 140 | 183 | 199 | 199 | 199 | 199 | 199 | 199 |
Registro LMC GIMEMA | 68 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 13 | 42 | 100 | 480 | 1194 | 1688 | 2044 | 2066 |
Studio GDM | 1 | 0 | 0 | 0 | 0 | 0 | 23 | 70 | 177 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 |
Studio H2WL | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 69 | 120 | 120 | 120 | 120 |
Studio Resveratrolo | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 32 | 125 | 192 | 192 | 192 | 192 | 192 |
Studio TOTEM | 44 | 0 | 0 | 0 | 0 | 5 | 107 | 329 | 547 | 775 | 987 | 1150 | 1349 | 1557 | 1775 | 1887 | 1887 |
Study ML17638: Rituximab | 33 | 19 | 98 | 158 | 235 | 235 | 235 | 235 | 235 | 235 | 235 | 235 | 235 | 235 | 235 | 235 | 235 |
TRANSLATE colon-retto | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 4 | 4 | 4 |
TRANSLATE mammella | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 6 | 7 | 7 |
TRANSLATE prostata | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TRANSLATE rene | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 3 |